Niraparib
- Generic Name
- Niraparib
- Brand Names
- Zejula
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N4O
- CAS Number
- 1038915-60-4
- Unique Ingredient Identifier
- HMC2H89N35
- Background
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal can...
- Indication
Niraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...
- Associated Conditions
- Advanced Epithelial Ovarian Cancer, Advanced Primary Peritoneal Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Advanced Fallopian Tubes Cancer
- Associated Therapies
- Maintenance therapy
Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
- Conditions
- Interventions
- Locations
- 🇳🇴
Norwegian Radium Hospital, Oslo, Norway
🇫🇮Tampere University Hospital, Tampere, Finland
🇳🇴Haukeland University Hospital, Bergen, Haukeland, Norway
European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 122
- Registration Number
- NCT03783949
- Locations
- 🇮🇹
Azienda Ospedaliero Bologna, Bologna, Italy
🇩🇪Universitätsklinikum Dresden, Dresden, Germany
🇦🇹Medical University of Innsbruck, Innsbruck, Austria
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- Conditions
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT03768063
- Locations
- 🇺🇸
Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama, United States
🇺🇸HonorHealth Research Institute - Pima - Virginia G. Piper Cancer Care Network, Scottsdale, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT03759600
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵Hirosaki University Hospital, Hirosaki, Aomori, Japan
🇯🇵Iwate Medical University Hospital, Morioka, Iwate, Japan
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 19
- Registration Number
- NCT03759587
- Locations
- 🇯🇵
Hirosaki University Hospital, Hirosaki, Aomori, Japan
🇯🇵Iwate Medical University Hospital, Morioka, Iwate, Japan
🇯🇵Kurume University Hospital, Kurume, Fukuoka, Japan
NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 141
- Registration Number
- NCT03752216
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
🇫🇷SASU Centre d'Oncologie et Radiothérapie 37, Chambray-lès-Tours, France
🇫🇷Groupe Hospitalier Mutualiste de Grenoble - Institut Daniel Hollard, Grenoble, France
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 765
- Registration Number
- NCT03748641
- Locations
- 🇺🇸
Massachusetts General, Boston, Massachusetts, United States
🇺🇸VA Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 77
- Registration Number
- NCT03695380
- Locations
- 🇺🇸
Medical College of Georgia; Obstetrics & Gynecolog, Augusta, Georgia, United States
🇺🇸Stephenson Cancer Center Investigational Pharmacy, Oklahoma City, Oklahoma, United States
🇺🇸Florida Hospital Cancer Institute; Clinical Research Department, Orlando, Florida, United States
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 196
- Registration Number
- NCT03651206
- Locations
- 🇫🇷
ICO Paul Papin, Angers, France
🇫🇷Centre Régional de Lutte contre le cancer - Institut Bergonié, Bordeaux, France
🇫🇷Centre François Baclesse, Caen, France
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 1402
- Registration Number
- NCT03602859
- Locations
- 🇬🇧
GSK Investigational Site, Wirral, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.